Why VERAXA Biotech AG (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D
July 14, 2026
Artificial intelligence is becoming an increasingly important component of pharmaceutical research, with companies using machine learning to analyze complex biological data, identify drug targets and improve clinical development decisions. Against that backdrop, VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, announced a collaboration with AI-focused research partner Ardigen that is intended […]
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development
July 13, 2026
VERAXA Biotech (NASDAQ: VRXA) announced a collaboration with AI-driven bioinformatics company Ardigen S.A. to support development of its BiTAC(R) pipeline of T-cell engagers and future antibody-drug conjugates. The partnership will initially focus on developing AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA’s BiTAC platform, which is designed to improve tumor targeting while […]
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Carl von Halem Interim Chief Financial Officer
July 13, 2026
VERAXA Biotech (NASDAQ: VRXA) announced the appointment of Carl von Halem as interim chief financial officer, succeeding Torsten Bürgermeister. The company said it is in the final stages of discussions with a permanent CFO candidate expected to support its next phase of expansion and operational growth, with an update to be provided in due course. […]
VERAXA Biotech AG (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership
July 8, 2026
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for its lead BiTAC(R) T-cell engager (“BiTAC(R)-TCE”) program, marking another step in preparing the company’s most advanced oncology candidate for future clinical development. The company announced that it has selected ATUM, a U.S.-based contract research organization specializing in […]
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5 Billion ADC Acquisition
July 6, 2026
VERAXA Biotech (NASDAQ: VRXA) operates in one of biotechnology’s most active partnering environments, with pharmaceutical companies continuing to commit billions of dollars to differentiated antibody therapeutics. The latest example came this week as Novartis agreed to acquire Myricx Bio for $1.1 billion upfront, plus up to $400 million in milestone payments, to gain access to the company’s novel N-myristoyltransferase inhibitor (“NMTi”) payload platform and […]
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy
July 6, 2026
VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update highlighting progress during the first half of 2026, including continued advancement of its proprietary BiTAC(R) platform and growing interest from potential pharmaceutical partners. The company said its pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (“ADC”) programs and […]
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program
July 2, 2026
VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager (“BiTAC-TCE”) program through a collaboration with ATUM, which will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines supporting IND/CTA-enabling activities and future clinical development. The collaboration follows encouraging preclinical data presented at the 2026 American Association for […]
Why VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals
July 1, 2026
Biotechnology investors often focus on clinical milestones, regulatory approvals, and commercial launches. Yet in antibody therapeutics, some of the largest value-creating events occur much earlier. Strategic licensing agreements, research collaborations, and acquisitions, have become important catalysts for companies developing differentiated technology platforms, and have resulted in significant market value shifts. That trend has been particularly […]
InvestorNewsBreaks – Xlife Sciences AG (SIX: XLS) Shareholders Approve All Annual Meeting Proposals
June 29, 2026
Xlife Sciences (SIX: XLS) announced that shareholders approved all proposals presented at the company’s Annual General Meeting, where 3,134,367 voting shares, representing 54.3% of the total share capital, were represented. Chairman David L. Deck said the company strengthened its portfolio during the past year and highlighted the Nasdaq listing of portfolio company Veraxa Biotech (NASDAQ: […]
VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline
June 24, 2026
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates in cancer treatment. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International […]
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline
June 24, 2026
VERAXA Biotech (NASDAQ: VRXA) an emerging developer of novel cancer therapies, announced it has expanded its laboratory footprint at its existing research and development site in Heidelberg, Germany, under a previously executed long-term lease agreement. The additional space will support planned growth of the company’s R&D team, installation of new laboratory equipment and completion of […]
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention
June 22, 2026
VERAXA Biotech (NASDAQ: VRXA) is highlighting partnering opportunities for its proprietary BiTAC(TM)-ADC and BiTAC-TCE technology platforms ahead of the BIO International Convention, taking place June 22-25 in San Diego. The company recently reported new proof-of-concept data supporting its BiTAC-ADC platform, which is designed to improve cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity. VERAXA […]
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Reports Proof-of-Concept Data for BiTAC-ADC Cancer Therapy Platform
June 18, 2026
VERAXA Biotech (NASDAQ: VRXA) announced new in vitro proof-of-concept data supporting its novel BiTAC(TM)-ADC technology platform, which is designed to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents. The company reported that BiTAC-ADCs demonstrated the ability to distinguish between breast cancer and healthy cells and achieved dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the […]
InvestorNewsBreaks – Why VERAXA Biotech AG (NASDAQ: VRXA) Is ‘One to Watch’
June 16, 2026
VERAXA Biotech (NASDAQ: VRXA) is advancing a diversified oncology pipeline spanning monoclonal antibodies, antibody-drug conjugates, bispecific ADCs and proprietary BiTAC-based therapeutic formats across multiple cancer indications. “The company is focused on the discovery and development of a new generation of antibody-based therapeutics for the treatment of solid tumors. VERAXA’s vision is to deliver the next […]
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Completes Business Combination and Begins Trading on Nasdaq
June 11, 2026
VERAXA Biotech (NASDAQ: VRXA) announced the successful closing of its previously announced business combination with Voyager Acquisition Corp. (NASDAQ: VACH), resulting in the formation of VERAXA Biotech AG, which will begin trading on the Nasdaq Capital Market under the ticker symbol VRXA, with warrants trading under VRXAW. The company is developing a pipeline of bispecific […]
VERAXA Biotech AG (NASDAQ: VRXA) Is ‘One to Watch’
June 11, 2026
VERAXA Biotech has successfully concluded a business combination with Voyager Acquisition Corp. (NASDAQ: VACH) and began trading on the NASDAQ Capital Market under the ticker symbol ‘VRXA’ on June 11, 2026. VERAXA Biotech (NASDAQ: VRXA) is a biotechnology company focused on the discovery and development of a new generation of antibody-based therapeutics for the treatment of […]
InvestorNewsBreaks – Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) Reports 99.67% Share Redemptions Ahead Of VERAXA Biotech Merger
March 11, 2026
Voyager Acquisition (NASDAQ: “VACHU,” “VACH,” “VACHW”) announced that holders of 25,217,315 Class A ordinary shares — representing approximately 99.67% of the shares outstanding — exercised their redemption rights in connection with the company’s planned business combination with VERAXA Biotech AG. Following the redemptions, approximately $885,556 will remain in Voyager’s trust account and 82,685 Class A shares will convert into […]